Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
India · Delayed Price · Currency is INR 101.00
-1.63 (-1.59%)
Sep 24, 2026, 3:29 PM IST
NSE:AAREYDRUGS Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 4,147 | 4,723 | 4,739 | 3,956 | 4,190 | 4,928 |
Other Revenue | 0 | - | - | 69.65 | - | 1.73 |
| 4,147 | 4,723 | 4,739 | 4,026 | 4,190 | 4,929 | |
Revenue Growth | -7.69% | -0.35% | 17.73% | -3.91% | -15.01% | 40.27% |
Cost of Revenue | 3,988 | 4,546 | 4,621 | 3,819 | 4,039 | 4,721 |
Gross Profit | 158.61 | 176.75 | 118.23 | 206.4 | 150.87 | 208.51 |
Selling, General & Admin | 56.44 | 13.8 | 16.74 | 14.21 | 15.54 | 20.46 |
Other Operating Expenses | 34.22 | 76.61 | 30.88 | 77.5 | 52.67 | 67.9 |
Operating Expenses | 122.81 | 118.94 | 67.06 | 108.69 | 83.95 | 108.24 |
Operating Income | 35.8 | 57.81 | 51.17 | 97.71 | 66.92 | 100.27 |
Interest Expense | -56.39 | -42.93 | -35.42 | -41.95 | -25.4 | -18.13 |
Interest & Investment Income | - | 46.3 | 56.04 | - | 26.33 | 20.09 |
Currency Exchange Gain (Loss) | - | 0.05 | 0.48 | -0.52 | -4.49 | 0.39 |
Other Non Operating Income (Expenses) | 62.6 | -7.09 | -11.23 | -1.8 | -3.26 | -2.24 |
EBT Excluding Unusual Items | 42.02 | 54.14 | 61.05 | 53.43 | 60.1 | 100.37 |
Other Unusual Items | - | - | -0.03 | - | - | - |
Pretax Income | 42.02 | 54.14 | 61.02 | 53.43 | 60.1 | 100.37 |
Income Tax Expense | 5.82 | 14.47 | 20.78 | 6.59 | 22.39 | 34.82 |
Net Income | 36.2 | 39.68 | 40.24 | 46.84 | 37.71 | 65.55 |
Net Income to Common | 36.2 | 39.68 | 40.24 | 46.84 | 37.71 | 65.55 |
Net Income Growth | -12.90% | -1.40% | -14.09% | 24.20% | -42.47% | 0.62% |
Shares Outstanding (Basic) | 28 | 28 | 28 | 25 | 25 | 24 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 25 | 25 | 24 |
Shares Change | 1.07% | - | 11.96% | -0.26% | 5.84% | 2.95% |
EPS (Basic) | 1.27 | 1.39 | 1.41 | 1.84 | 1.48 | 2.72 |
EPS (Diluted) | 1.27 | 1.39 | 1.41 | 1.84 | 1.48 | 2.72 |
EPS Growth | -13.95% | -1.42% | -23.37% | 24.32% | -45.59% | -2.36% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -22.72 | 50.96 | -37.16 | -23.25 | -17.03 |
Free Cash Flow Per Share | - | -0.80 | 1.79 | -1.46 | -0.91 | -0.71 |
Gross Margin | 3.82% | 3.74% | 2.50% | 5.13% | 3.60% | 4.23% |
Operating Margin | 0.86% | 1.22% | 1.08% | 2.43% | 1.60% | 2.03% |
Profit Margin | 0.87% | 0.84% | 0.85% | 1.16% | 0.90% | 1.33% |
Free Cash Flow Margin | - | -0.48% | 1.07% | -0.92% | -0.56% | -0.34% |
EBITDA | 66.6 | 86.34 | 70.62 | 114.69 | 82.66 | 120.15 |
EBITDA Margin | 1.61% | 1.83% | 1.49% | 2.85% | 1.97% | 2.44% |
D&A For EBITDA | 30.8 | 28.53 | 19.45 | 16.98 | 15.74 | 19.88 |
EBIT | 35.8 | 57.81 | 51.17 | 97.71 | 66.92 | 100.27 |
EBIT Margin | 0.86% | 1.22% | 1.08% | 2.43% | 1.60% | 2.03% |
Effective Tax Rate | 13.84% | 26.72% | 34.05% | 12.34% | 37.25% | 34.69% |
Revenue as Reported | 4,209 | 4,784 | 4,838 | 4,026 | 4,217 | 4,954 |
Advertising Expenses | - | 0.89 | 3.36 | 1.71 | 2.56 | 3.89 |